United Therapeutics (UTHR) Non Operating Income (2009 - 2026)

United Therapeutics has disclosed Non Operating Income across 18 years of filings, most recently posting -$7.5 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at -$7.5 million, down 74.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $89.1 million (up 20.41% YoY), and the FY2025 annual result was $48.9 million, up 743.1% from the prior year.
• Non Operating Income came in at -$7.5 million for Q1 2026 at United Therapeutics, down from $47.2 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $102.8 million in Q4 2023 to a low of -$51.8 million in Q2 2022.
• The 5-year median for Non Operating Income is $5.8 million (2022), against an average of $16.0 million.
• Across the five-year window, Non Operating Income tumbled 1818.52% in 2022 and surged 6000.0% in 2024, its largest moves.
• United Therapeutics' Non Operating Income stood at $5.8 million in 2022, then jumped by 1672.41% to $102.8 million in 2023, then tumbled by 102.53% to -$2.6 million in 2024, then jumped by 1915.38% to $47.2 million in 2025, then sank by 115.89% to -$7.5 million in 2026.
• The last three Non Operating Income figures came in at -$7.5 million (Q1 2026), $47.2 million (Q4 2025), and $49.5 million (Q3 2025), per Business Quant data.